Cargando…
The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers
OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437324/ https://www.ncbi.nlm.nih.gov/pubmed/30915878 http://dx.doi.org/10.1177/1470320319839525 |
_version_ | 1783406942038786048 |
---|---|
author | Fukuda, Michio Isobe-Sasaki, Yukako Sato, Ryo Miura, Toshiyuki Mizuno, Masashi Ono, Minamo Kiyono, Ken Yamamoto, Yoshiharu Hayano, Junichiro Ohte, Nobuyuki |
author_facet | Fukuda, Michio Isobe-Sasaki, Yukako Sato, Ryo Miura, Toshiyuki Mizuno, Masashi Ono, Minamo Kiyono, Ken Yamamoto, Yoshiharu Hayano, Junichiro Ohte, Nobuyuki |
author_sort | Fukuda, Michio |
collection | PubMed |
description | OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect the study results. METHODS: In this subanalysis, 20 patients with chronic kidney disease (14 men; age 61±15 years) were divided into three groups: patients with coadministration of L-type CCB, patients without coadministration of CCB, and patients with coadministration of sympathoinhibitory (L/T- or L/T/N-type) CCB. λ(25s) was calculated separately in daytime and nighttime. RESULTS: Daytime λ(25s) at baseline was higher in patients with L-type CCB coadministration (0.62±0.18, n = 5) compared with those without CCB (0.49±0.13, n = 11) and those with sympathoinhibitory CCB (0.46±0.06, n = 4). The relationship between the changes in daytime λ(25s) and systolic blood pressure was positive in patients with L-type CCB coadministration, whereas the relationship was inverse in the other two groups. A larger decrease in daytime λ(25s) was shown in patients with L-type CCB coadministration compared with those in the other two groups. CONCLUSIONS: CCBs, as well as diuretics, are recommended as second-line antihypertensive agents. Our results suggested that ARBs can overwhelm the activation of sympathetic nerve activity stimulated by coadministration of L-type CCBs. |
format | Online Article Text |
id | pubmed-6437324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64373242019-04-03 The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers Fukuda, Michio Isobe-Sasaki, Yukako Sato, Ryo Miura, Toshiyuki Mizuno, Masashi Ono, Minamo Kiyono, Ken Yamamoto, Yoshiharu Hayano, Junichiro Ohte, Nobuyuki J Renin Angiotensin Aldosterone Syst Original Article OBJECTIVE: In our recent study, non-Gaussianity of heart rate variability (λ(25s)), an indicator of sympathetic nerve activity, did not change during two-day treatment with the angiotensin II type 1 receptor blocker (ARB) azilsartan. Coadministration of calcium channel blockers (CCBs) might affect the study results. METHODS: In this subanalysis, 20 patients with chronic kidney disease (14 men; age 61±15 years) were divided into three groups: patients with coadministration of L-type CCB, patients without coadministration of CCB, and patients with coadministration of sympathoinhibitory (L/T- or L/T/N-type) CCB. λ(25s) was calculated separately in daytime and nighttime. RESULTS: Daytime λ(25s) at baseline was higher in patients with L-type CCB coadministration (0.62±0.18, n = 5) compared with those without CCB (0.49±0.13, n = 11) and those with sympathoinhibitory CCB (0.46±0.06, n = 4). The relationship between the changes in daytime λ(25s) and systolic blood pressure was positive in patients with L-type CCB coadministration, whereas the relationship was inverse in the other two groups. A larger decrease in daytime λ(25s) was shown in patients with L-type CCB coadministration compared with those in the other two groups. CONCLUSIONS: CCBs, as well as diuretics, are recommended as second-line antihypertensive agents. Our results suggested that ARBs can overwhelm the activation of sympathetic nerve activity stimulated by coadministration of L-type CCBs. SAGE Publications 2019-03-27 /pmc/articles/PMC6437324/ /pubmed/30915878 http://dx.doi.org/10.1177/1470320319839525 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Fukuda, Michio Isobe-Sasaki, Yukako Sato, Ryo Miura, Toshiyuki Mizuno, Masashi Ono, Minamo Kiyono, Ken Yamamoto, Yoshiharu Hayano, Junichiro Ohte, Nobuyuki The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title | The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title_full | The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title_fullStr | The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title_full_unstemmed | The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title_short | The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
title_sort | angiotensin ii type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437324/ https://www.ncbi.nlm.nih.gov/pubmed/30915878 http://dx.doi.org/10.1177/1470320319839525 |
work_keys_str_mv | AT fukudamichio theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT isobesasakiyukako theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT satoryo theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT miuratoshiyuki theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT mizunomasashi theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT onominamo theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT kiyonoken theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT yamamotoyoshiharu theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT hayanojunichiro theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT ohtenobuyuki theangiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT fukudamichio angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT isobesasakiyukako angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT satoryo angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT miuratoshiyuki angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT mizunomasashi angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT onominamo angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT kiyonoken angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT yamamotoyoshiharu angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT hayanojunichiro angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers AT ohtenobuyuki angiotensiniitype1receptorblockerazilsartancanoverwhelmthesympatheticnerveactivationstimulatedbycoadministrationofcalciumchannelblockers |